GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Current Accrued Expense

Apollomics (Apollomics) Current Accrued Expense : $3.19 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Current Accrued Expense?

Apollomics's Current Accrued Expense for the quarter that ended in Dec. 2023 was $3.19 Mil.

Apollomics's quarterly Current Accrued Expense increased from Dec. 2022 ($4.14 Mil) to Jun. 2023 ($5.79 Mil) but then declined from Jun. 2023 ($5.79 Mil) to Dec. 2023 ($3.19 Mil).

Apollomics's annual Current Accrued Expense declined from Dec. 2021 ($5.39 Mil) to Dec. 2022 ($4.14 Mil) and declined from Dec. 2022 ($4.14 Mil) to Dec. 2023 ($3.19 Mil).


Apollomics Current Accrued Expense Historical Data

The historical data trend for Apollomics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Current Accrued Expense Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
3.84 5.39 4.14 3.19

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Accrued Expense Get a 7-Day Free Trial 5.39 5.87 4.14 5.79 3.19

Apollomics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Apollomics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Apollomics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollomics (Apollomics) Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.